Comparision of Dual PI-3K/mTOR Inhibitors with mTOR Inhibitors Using a Pre-Clinical Model of Acute Lymphoblastic Leukemia

被引：0
作者：
Wong, Jacky [1 ]
Welschinger, Robert [1 ]
Baraz, Rana [1 ]
Weiss, Jocelyn [1 ]
Bradstock, Ken
Bendall, Linda J.
机构：
[1] Westmead Hosp, Westmead Millenium Inst, Westmead Inst Canc Res, Sydney, NSW, Australia
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1336 / 1336
页数：1
相关论文
共 50 条
  • [1] Efficacy of dual PI-3K and mTOR inhibitors in Vitro and in Vivo in acute lymphoblastic leukemia
    Wong, Jacky
    Welschinger, Robert
    Hewson, John
    Bradstock, Kenneth F.
    Bendall, Linda J.
    ONCOTARGET, 2014, 5 (21) : 10460 - 10472
  • [2] Application of Dual PI-3K/mTOR Inhibitors Is Not Always Superior to Inhibition of mTOR Alone
    Wong, Jacky
    Welschinger, Robert
    Baraz, Rana
    Bradstock, Kenneth Francis
    Bendall, Linda J.
    BLOOD, 2011, 118 (21) : 1526 - 1526
  • [3] Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic Leukemia
    Badura, Susanne
    Tesanovic, Tamara
    Pfeifer, Heike
    Wystub, Sylvia
    Nijmeijer, Bart A.
    Liebermann, Marcus
    Falkenburg, J. H. Frederik
    Ruthardt, Martin
    Ottmann, Oliver G.
    PLOS ONE, 2013, 8 (11):
  • [4] Design and synthesis of dual PI3K/mTor inhibitors
    Olivero, Alan
    Heffron, Timothy
    Berry, Leanne
    Berry, Megan
    Castanedo, Georgette
    Chang, Christine
    Dotson, Jennafer
    Friedman, Lori
    Goldsmith, Richard
    Lesnick, John
    Lewis, Cristina
    Mathieu, Simon
    Nonomiya, Jim
    Pang, Jodie
    Peterson, David
    Prior, Wei Wei
    Salphati, Laurent
    Sampath, Deepak
    Sutherlin, Daniel
    Tsui, Vickie
    Ultsch, Mark
    Wang, Shumei
    Wiesmann, Christian
    Wong, Susan
    Zhu, Bing-Yan
    Chuckowree, Irina
    Folkes, Adrian
    Shuttleworth, Steve
    CANCER RESEARCH, 2009, 69
  • [5] Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model
    Hasan, Md. Nabiul
    Queudeville, Manon
    Trentin, Luca
    Eckhoff, Sarah Mirjam
    Bronzini, Ilaria
    Palmi, Chiara
    Barth, Thomas
    Cazzaniga, Giovanni
    te Kronnie, Geertruy
    Debatin, Klaus-Michael
    Meyer, Lueder Hinrich
    ONCOTARGET, 2015, 6 (03) : 1382 - 1395
  • [6] Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?
    Sabbah, D. A.
    Brattain, M. G.
    Zhong, H.
    CURRENT MEDICINAL CHEMISTRY, 2011, 18 (36) : 5528 - 5544
  • [7] Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
    Chen, Jiezhong
    Zhao, Kong-Nan
    Li, Rui
    Shao, Renfu
    Chen, Chen
    CURRENT MEDICINAL CHEMISTRY, 2014, 21 (26) : 3070 - 3080
  • [8] Omipalisib inspired macrocycles as dual PI3K/mTOR inhibitors
    Alvarez, Rosa M.
    Belen Garcia, Ana
    Riesco-Fagundo, Concepcion
    Martin, Jose, I
    Varela, Carmen
    Rodriguez Hergueta, Antonio
    Gonzalez Cantalapiedra, Esther
    Oyarzabal, Julen
    Di Geronimo, Bruno
    Lorenzo, Milagros
    Isabel Albarran, M.
    Cebria, Antonio
    Cebrian, David
    Martinez-Gonzalez, Sonia
    Blanco-Aparicio, Carmen
    Pastor, Joaquin
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 211
  • [9] Pre-clinical efficacy of dual PI3K δ/γ inhibitors in airway inflammation
    Nagarathnam, Dhanapalan
    Govindarajulu, Babu
    Routhu, Kasiviswanath
    Rajagopalan, Prasanna
    Veeraraghavan, Sridhar
    Viswanadha, Srikant
    Vakkalanka, Swaroop
    JOURNAL OF IMMUNOLOGY, 2012, 188
  • [10] DUAL INHIBITION OF THE MTOR AND PI-3K PATHWAYS INDUCES ANTI-PROLIFERATIVE EFFECTS IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) AND PROLONGS SURVIVAL IN VIVO
    Wong, S. K.
    Welschinger, R.
    Baraz, R.
    Bradstock, K.
    Bendall, L. J.
    EXPERIMENTAL HEMATOLOGY, 2010, 38 (09) : S43 - S43
12345